Cargando…

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma

Inducible genetically defined mouse models of cancer uniquely facilitate the investigation of early events in cancer progression, however, there are valid concerns about the ability of such models to faithfully recapitulate human disease. We developed an inducible mouse model of progressive lung ade...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neidler, Sarah, Kruspig, Björn, Hewit, Kay, Monteverde, Tiziana, Gyuraszova, Katarina, Braun, Attila, Clark, William, James, Daniel, Hedley, Ann, Nieswandt, Bernhard, Shanks, Emma, Dick, Craig, Murphy, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562816/ https://www.ncbi.nlm.nih.gov/pubmed/31032816 http://dx.doi.org/10.3390/cancers11050600

Ejemplares similares

IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells
por: Rodrigues, Felipe Silva, et al.
Publicado: (2020)

Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
por: Farahmand, Pooyeh, et al.
Publicado: (2023)

Brown Tumors Belong to the Spectrum of KRAS-driven Neoplasms
por: Turek, Daniel, et al.
Publicado: (2022)

A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor
por: Hewit, Kay, et al.
Publicado: (2018)

Clinical Relevance of KRAS in Human Cancers
por: Jančík, Sylwia, et al.
Publicado: (2010)

Iron out KRAS-driven cancer
por: Lei, Guang, et al.
Publicado: (2022)

Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment
por: Rushworth, Linda K., et al.
Publicado: (2019)

Mice Lacking the SLAM Family Member CD84 Display Unaltered Platelet Function in Hemostasis and Thrombosis
por: Hofmann, Sebastian, et al.
Publicado: (2014)

KRAS-driven ROS promote malignant transformation
por: Suh, Yongjoon, et al.
Publicado: (2015)

Twists and turns in Kras-driven tumor initiation
por: Maru, Yoshiaki, et al.
Publicado: (2021)

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer
por: Westcott, Peter M. K., et al.
Publicado: (2014)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
por: Arner, Emily N., et al.
Publicado: (2019)

Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice
por: Sherwood, James L, et al.
Publicado: (2017)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

A Neuronal Relay Mediates a Nutrient Responsive Gut/Fat Body Axis Regulating Energy Homeostasis in Adult Drosophila
por: Scopelliti, Alessandro, et al.
Publicado: (2019)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Targeting copper metabolism to defeat KRAS-driven colorectal cancer
por: Aubert, Léo, et al.
Publicado: (2020)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Hyun, Soonsil, et al.
Publicado: (2021)

Description of the “Brigade Case”
por: Hewit, H. S.
Publicado: (1861)

Comparison of the central human and mouse platelet signaling cascade by systems biological analysis
por: Balkenhol, Johannes, et al.
Publicado: (2020)

PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
por: Huang, Zhangsen, et al.
Publicado: (2021)

Salivary creatinine and urea are higher in an experimental model of acute but not chronic renal disease
por: Kovalčíková, Alexandra, et al.
Publicado: (2018)

Calcium signalling links MYC to NUAK1
por: Monteverde, T, et al.
Publicado: (2018)

A KRAS-responsive long non-coding RNA controls microRNA processing
por: Shi, Lei, et al.
Publicado: (2021)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

Cancer Stemness in Apc- vs. Apc/KRAS-Driven Intestinal Tumorigenesis
por: Ghazvini, Mehrnaz, et al.
Publicado: (2013)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
por: Mokhlis, Hamada A., et al.
Publicado: (2018)

KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
por: Pupo, Emanuela, et al.
Publicado: (2019)

An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
por: von Karstedt, Silvia, et al.
Publicado: (2020)

KRAS-driven model of Gorham-Stout disease effectively treated with trametinib
por: Homayun-Sepehr, Nassim, et al.
Publicado: (2021)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
por: Kostyrko, Kaja, et al.
Publicado: (2023)

Diet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis
por: Ramadori, Giorgio, et al.
Publicado: (2015)

Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
por: Muzumdar, Mandar Deepak, et al.
Publicado: (2016)

STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis
por: D'Amico, Stephen, et al.
Publicado: (2018)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
por: Ali, Moiez, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eq3c7qs5ij6173snb3qqok8j7i